• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>American Journal of Physiology - Heart and Circulatory Physiology >PPAR-γ agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension
【2h】

PPAR-γ agonist rosiglitazone reverses increased cerebral venous hydraulic conductivity during hypertension

机译：PPAR-γ激动剂罗格列酮逆转高血压期间脑静脉液压传导性的增加

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonists have been shown to protect the cerebral vasculature, including the blood-brain barrier. In the present study, we investigated the effect of the PPAR-γ agonist rosiglitazone on changes in venous permeability during chronic hypertension induced by nitric oxide synthase inhibition. Female Sprague-Dawley rats were either treated with NG-nitro-l-arginine methyl ester (l-NAME; 0.5 g/l in drinking water) for 5 wk (HTN; n = 8), l-NAME for 5 wk plus the PPAR-γ agonist rosiglitazone (20 mg/kg in food) for the last 3 wk (HTN + Rosi; n = 5), l-NAME for 5 wk plus the superoxide dismutase mimetic Tempol (1 mmol/l in drinking water) for the last 3 wk (HTN + Tempol; n = 8), or were untreated controls (n = 9). Fluid filtration (Jv/S) and hydraulic conductivity (Lp) of cerebral veins were compared in vitro between groups after a step increase in pressure from 10 to 25 mmHg to mimic the change in hydrostatic pressure during acute hypertension. Hypertension increased Jv/S by 2.2-fold and Lp by 3.2-fold. Rosiglitazone treatment after 2 wk of hypertension completely reversed the increased Jv/S and Lp that occurred during hypertension, whereas Tempol had no effect. These results demonstrate that rosiglitazone was effective at reversing changes in venous permeability that occurred during chronic hypertension, an effect that does not appear to be related to its antioxidant properties. Our findings suggest that PPAR-γ may be a key regulator of blood-brain barrier permeability and a potential therapeutic target during hypertension.
机译：过氧化物酶体增殖物激活受体-γ（PPAR-γ）激动剂已被证明可以保护脑血管系统，包括血脑屏障。在本研究中，我们研究了PPAR-γ激动剂罗格列酮对一氧化氮合酶抑制诱导的慢性高血压过程中静脉通透性变化的影响。将雌性Sprague-Dawley大鼠用N G -硝基-1-精氨酸甲酯（l-NAME；饮用水中0.5 g / l）处理5周（HTN； n = 8），前5周的l-NAME加PPAR-γ激动剂罗格列酮（食品中20 mg / kg）（HTN + Rosi; n = 5），前5周的l-NAME加超氧化物歧化酶模拟物Tempol（1连续3周（HTN + Tempol; n = 8），或未经处理的对照组（n = 9），为饮用水中的mmol / l）。在将压力从10 mmHg逐步增加到25 mmHg以模拟急性高血压期间静水压力的变化后，在两组之间进行了体外比较组之间的脑静脉液过滤（Jv / S）和液压传导率（Lp）。高血压使Jv / S升高2.2倍，Lp升高3.2倍。高血压2周后接受罗格列酮治疗可完全逆转高血压期间发生的Jv / S和Lp升高，而Tempol无作用。这些结果表明，罗格列酮可有效逆转慢性高血压期间发生的静脉通透性变化，这种作用似乎与其抗氧化特性无关。我们的发现表明，PPAR-γ可能是血脑屏障通透性的关键调节剂，并且可能是高血压期间的潜在治疗靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号